By Parexel Biotech
The COVID-19 pandemic accelerated the adoption of decentralized clinical trials (DCTs) by biopharma companies. The clinician-patient relationship will always be key to clinical trials, but decentralized aspects such as direct-to-patient shipments and telehealth are here to stay.
Here are four things we have learned about DCTs that biotech companies can consider when designing a decentralized or hybrid trial.
DCTs can be better for patients
Patient-centricity is a significant advantage of DCTs. You can make a trial more patient-centric, reducing the burden on patients by not requiring them to travel to a site for every interaction, says Ada Wowk, Director of the Patient Innovation Center for Parexel.
Newsradio WJPF interview with Doug Kimmel & Steve Mitchell | May 10
wjpf.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wjpf.com Daily Mail and Mail on Sunday newspapers.
Top Ten Rules For Success In Decentralized Trials
clinicalleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from clinicalleader.com Daily Mail and Mail on Sunday newspapers.
Bringing Clinical Trials To Patients With The Decentralized Model
By Rosamund Round, Vice President, Patient Innovation Center, Parexel®
Before the pandemic, Parexel was experienced at executing decentralized clinical trials to improve patient access and experiences. Since, COVID-19, which has had a huge impact on global clinical trials, sponsors, CROs, sites, and patients have pivoted to adapt to a more home- or community-based approach. More than 100 DCTs later, Parexel is at the forefront of industry change.
“Everything we do is built around the patient and caregiver to make participation as easy as possible.” says Rosamund Round, Vice President of Parexel’s Patient Innovation Center. Central to navigating the dynamic research landscape is Parexel’s ability to harness and apply patient insights during DCT planning to ensure that every part of the strategy is formulated with the patient in mind. This approach, along with expertise in global regulatory requirements, tech